TRANSCRIPT

Q4 2024 — Prepared remarks

Q4 2024PDF · 15 pages229 KB
1
Philip Morris International Inc.
2024 Fourth-Quarter Conference Call
February 6, 2025
JAMES BUSHNELL
(SLIDE 1.)
Welcome. Thank you for joining us. Earlier today, we issued a press release containing
detailed information on our 2024 fourth-quarter and full-year results. The press release
is available on our website at www.pmi.com.
(SLIDE 2.)
A glossary of terms, including the definition for smoke-free products as well as
adjustments, other calculations and reconciliations to the most directly comparable
U.S. GAAP measures for non-GAAP financial measures cited in this presentation are
available in Exhibit 99.2 to the company's Form 8-K dated February 6, 2025, and on
our Investor Relations website.
(SLIDE 3.)
Today’s remarks contain forward-looking statements and projections of future results.
I direct your attention to the Forward-Looking and Cautionary Statements disclosure
in today’s presentation and press release for a review of the various factors that could
cause actual results to differ materially from projections or forward-looking statements.
I’m joined today by Jacek Olczak, Chief Executive Officer, and Emmanuel Babeau,
Chief Financial Officer.
Over to you, Jacek.

-- 1 of 15 --

2
JACEK OLCZAK
(SLIDE 4.)
Thank you, James, and welcome everyone.
We delivered an outstanding performance in 2024, with all key elements of the
business contributing strongly to deliver best-in-class organic top and bottom-line
growth. This resulted in significant acceleration in adjusted diluted EPS growth in both
currency-neutral and dollar terms, as we mitigated substantial currency headwinds.
Our business outperformed the industry and consumer packaged goods overall, with
growth across all categories to deliver our fourth consecutive year of positive volumes.
IQOS continued its strong underlying momentum, with continued excellent growth in
Japan, robust progress in Europe despite the EU characterizing flavor ban, and further
strong growth in other global markets. Importantly, the growth of IQOS is increasingly
profitable as the benefits of scale and pricing more than offset continued substantial
growth investments, including brand-building activities and innovations on devices and
consumables.
ZYN once again delivered strong growth in the U.S., as 2023’s demand acceleration
continued in 2024. This resulted in short-term supply challenges which we have
progressively addressed throughout the year, working towards our goal of matching
existing user demand. As we unlock further capacity, we will be in a position to explore
the full potential of this dynamic category. Outside the U.S., shipments grew by +75%
as we increased our global presence in nicotine pouches to 37 markets.
In e-vapor, VEEV is progressively contributing to growth with encouraging volume
momentum in closed pods and a strengthening market position, with a premium offer.
Our combustible business performed well on all metrics. We delivered double-digit
gross profit growth in Q4 and around +7% organically for the year, led by strong
pricing, resilient volumes in certain markets, and the ongoing benefits of our cost
actions.
Overall, our strong performance across all categories and regions drove meaningful
operating leverage, notably in our smoke-free business, alongside cost efficiency
initiatives across the entire value chain. This enabled us to deliver operating cash flow
and adjusted diluted EPS above our expectations at the start of the year, despite
ongoing currency and input cost headwinds. Our transformation journey and growth

-- 2 of 15 --

3
drivers have excellent momentum, and we are confident in our ability to deliver
sustainable growth and returns in 2025 and beyond.
(SLIDE 5.)
We achieved several key milestones in our smoke-free journey over the past year,
including the 10 year anniversaries of IQOS and ZYN. Our smoke-free business is
large, profitable and growing fast. Our total smoke-free net revenues reached almost
$15 billion in 2024. Combined with a strong combustibles performance, our company
also surpassed $10 billion in adjusted net earnings for the first time.
Our smoke-free business reached 40% of total PMI net revenues in the fourth quarter,
and around 42% of adjusted gross profit, as our transformation becomes increasingly
profitable. In our top five markets by operating income, around 60% of net revenues
were smoke-free.
We have deployed our smoke-free multi-category strategy across almost half of the
95 markets with smoke-free products and we close the year with over 38.5 million
estimated adult users across heat-not-burn, oral and e-vapor.
Our oral smoke-free business surpassed 1 billion cans, including 644 million cans of
nicotine pouches. The ZYN brand continues to resonate with adult nicotine consumers
across the U.S., where it is the number one smoke-free brand and fourth biggest
nicotine brand, and internationally. We are also very pleased that the robust science
and responsible marketing practices behind ZYN were recognized by the FDA through
the recent marketing authorizations of all currently commercialized U.S. ZYN variants,
making ZYN the first and only authorized nicotine pouch brand in the United States.
We remain at the forefront of the effort to increase understanding of smoke-free
products and advance Tobacco Harm Reduction among consumers and regulators.
We are encouraged by the increasing number of governments adopting tobacco harm
reduction policies to incentivize switching to reduced risk nicotine products instead of
continuing to smoke, which is sound public health policy. A number of markets are also
moving favorably with regard to robust regulation of nicotine pouches and e-vapor.
Regretfully there is also resistance in many places, often driven by ideology not facts
and science, and therefore a considerable amount of work remains.
While reaching important milestones is pleasing, after 10 years we are still in the early
stages of industry transformation. With our strong brands, and our innovative and
commercial capabilities, we have many years of opportunities and growth ahead. I
look forward to sharing more with you at the upcoming CAGNY conference on
February 19th.

-- 3 of 15 --

4
I will now hand over to Emmanuel to discuss our results and outlook in more detail.
EMMANUEL BABEAU
(SLIDE 6.)
Thank you, Jacek.
I will start with the headline financials for the year.
As Jacek said, this was a truly outstanding year of growth across our business as the
rapid progress of IQOS and U.S. ZYN was complemented by emerging growth
contributions from VEEV and ZYN internationally and a much-improved combustible
performance.
We delivered in line or above our last-communicated expectations across key metrics.
Organic net revenue growth of +9.8%, adjusted IMS and shipments of HTUs, and
combustible pricing of +8.7% were strong. Excellent total shipment volume growth of
+2.9%, including ZYN and combustible volumes, performed at the top end of our
expectations. Coupled with accelerated cost efficiencies, this led to better-than-
expected +14.9% organic operating income growth and +15.6% currency-neutral
adjusted diluted EPS growth.
Our clear focus on delivering performance in dollar terms was reflected in the +9.3%
growth in adjusted diluted EPS. As a result, we achieved record operating cashflow of
$12.2 billion, which was significantly above both our initial and most recent forecast,
supported by excellent profit delivery and favorable working capital. Combined with
strong adjusted EBITDA, this allowed us to significantly improve our leverage ratio,
which I’ll come back to later.
(SLIDE 7.)
We closed the year strongly in Q4, with organic net revenue growth of +7.3% despite
the impact of timing and comparison effects, most notably related to Red Sea
disruption, the EU Characterizing flavor ban for HTUs, and pre-launch ILUMA i device
shipments. This was driven by total volume growth of +2.3%, alongside positive
smoke-free mix and robust pricing.
Combined with operating leverage and manufacturing efficiencies, we delivered close
to +12% organic OI growth and +10% currency-neutral adjusted diluted EPS growth.

-- 4 of 15 --

5
In dollar terms, adjusted OI increased +15% and adjusted diluted EPS grew +14% to
$1.55. This includes a positive currency impact of 6 cents, which reflects an
unfavorable transactional impact in the prior year in Argentina as well as the move to
hyperinflationary accounting in Egypt, which also had a negative impact on our organic
growth of around 1 point on net revenues, and 2 points on OI.
The non-cash impairment of our RBH equity investment had no impact on our adjusted
financials. In future we may benefit from RBH dividend income, but we do not include
any impact in our 2025 forecast at this time.
(SLIDE 8.)
Let’s take a step back and consider 2024 in the context of the last few years. Our
organic top-line delivery has been consistently strong since the pandemic and further
accelerated this year, as both smoke-free products and combustibles stepped up their
trajectory.
Clearly, 2024 was also a stand-out year for adjusted diluted EPS growth. The
profitability of our smoke-free business accelerated, due to the operating leverage of
IQOS’ increasing scale, favorable unit economics, pricing, efficiencies and the
impressive accretion from ZYN’s rapid growth at superior U.S. margins.
We also benefitted from a notably robust combustible performance, which provides
important structural support for our transformation journey.
(SLIDE 9.)
These dynamics are further demonstrated by the organic top-line and gross profit
growth of both categories in the year.
Our smoke-free business accelerated to +17% net revenue growth and +23% gross
profit growth, reaching close to $10 billion in gross profit. This drove an impressive
+330 basis points of organic gross margin expansion, fueled by the factors I just
mentioned.
On the combustibles side, net revenues and gross profit grew organically by +6% and
+7% respectively, leading to +60 basis points of organic gross margin expansion. Our
combustibles business is once again contributing positively, with pricing and cost
efficiencies more than compensating for the third year of significant input cost
headwinds, which we expect to ease in 2025.

-- 5 of 15 --

6
I would also note that adjusted gross margins for smoke-free products were +490
basis points higher than combustibles in Q4 and +270 basis points higher for the year
overall at 66.6%. While we continue to target gross margin expansion in combustibles,
we expect this gap to grow over time as we continue to drive profitable growth from
smoke-free products while investing in new markets, brand-building and innovation.
(SLIDE 10.)
Taking a closer look at our volume performance, we delivered our fourth consecutive
year of shipment growth, up +2.3% in the fourth quarter, and close to 3% for the full
year. Including our VEEV e-vapor business in equivalent units, this growth was +2.4%
and +3% respectively. Our total 2024 smoke-free volume growth including VEEV was
+13.5% or 19 billion unit equivalents, an acceleration compared to 2023.
For IQOS, we delivered HTU adjusted IMS growth of close to +13%, and shipment
volumes of 139.7 billion, both broadly in line with our expectations. Adjusted IMS
growth accelerated in H2 to close to +14%, essentially in line with our target of +14 to
15%. This includes dynamic growth of close to +11% in Europe, with strong
momentum across the large majority of markets.
As I touched on earlier, Q4 HTU shipment growth includes the impact of additional
shipments in the prior year to prepare for the EU characterizing flavor ban, and the
phasing effect of additional shipments to Japan in H1 notably due to Red Sea
disruption.
Our oral smoke-free business grew 2024 shipment volumes by +24.6%, including
ZYN’s U.S. growth of +51% to 581 million cans. Snus and Moist snuff volumes were
stable.
Cigarette shipments grew by +0.6%, approximately in line with the estimated growth
of the international industry. The growth of the cigarette market can be largely
attributed to growth in markets where smoke-free products are not permitted such as
Turkey, Brazil and India. Excluding such markets, we observe a low single-digit
decline, consistent with historic trends.
(SLIDE 11.)
Our strong full-year top-line growth of almost +10% was again achieved through a
combination of volume growth, pricing and the positive mix impact of the shift to
smoke-free products. Pricing contributed +6.2%, reflecting almost +9% combustible
pricing and +2% for smoke-free products.

-- 6 of 15 --

7
Smoke-free also drove a positive mix impact of +1.9%, due to the higher net revenue
per unit of both IQOS HTUs and ZYN. Oral smoke-free products contributed +2.2% to
overall group top-line growth for the year, demonstrating ZYN’s role as a meaningful
accelerator to our performance.
As in prior years, geographic mix was negative primarily due to combustibles, but to a
lesser degree given robust net revenue growth in Europe.
(SLIDE 12.)
Moving down to adjusted operating margins, we delivered full-year organic expansion
of +180 basis points, and +100 basis points in dollar terms, comfortably achieving our
objective of expansion on both bases. This reflects a strong Q4 with OI margins
expanding organically by +140 basis points, as gross margin expansion outweighed
SG&A investments.
Full-year gross margins increased organically by +160 basis points, and by +120 basis
points in dollar terms.
SG&A drove +20 basis points of margin expansion, enabled by cost efficiency actions,
despite significant reinvestment and commercial support behind our smoke-free
business and U.S. capabilities, especially in H2.
We delivered over $750 million in gross cost efficiencies for the year, with COGS
productivities across smoke-free and combustibles, and continued back-office
savings. This places us well on track for our ’24-26 target of $2 billion.
(SLIDE 13.)
Focusing on our smoke-free business, we grew our estimated user base by over five
million people in 2024, to reach approximately 38.6 million legal-age users as of
December 31st. This includes an estimated 32.2 million IQOS users, 5.7 million Oral
users and 1.0 million VEEV users.
I’m pleased to report robust IQOS user growth of +3.4 million versus prior year and
+1.5 million during H2. This growth is broad-based and consistent with recent years,
despite limited new market openings and the EU characterizing flavor ban.
Oral added +1.5 million users year-on-year driven by ZYN’s continued strong traction
with legal-age nicotine consumers in the U.S., despite supply constraints.

-- 7 of 15 --

8
(SLIDE 14.)
Zooming in now on IQOS. Strong user momentum is reflected in adjusted IMS
volumes with 2024 growth of over 15 billion units, in line with the prior year despite the
impact of the EU flavor ban. This growth is also in line with the five-year average, and
more than 1 billion units above when excluding contributions from markets launched
in the current or preceding year.
Importantly, following the roll-out of IQOS ILUMA and with the increasing scale of the
business, the profitability of IQOS is growing strongly. We illustrate this here with the
indexed product contribution over time at constant exchange rates. As we’ve explained
before, the upfront costs of a business-to-consumer operation results in declining
infrastructure cost per user over time as the user count grows in a market. This is a
dynamic we expect to continue in future.
(SLIDE 15.)
Turning to IQOS in Europe. As expected, HTU adjusted IMS growth accelerated
strongly in H2 to almost +11%, following H1 progression of around 8%. This resulted
in robust +9.4% growth overall for the year, despite the significant disruption of the
characterizing flavor ban.
This double-digit adjusted IMS growth in H2 was driven by strong progress in a large
number of markets, including growth of around 20% or more in markets such as
Bulgaria, Greece, Germany, Romania and Spain, while growth was less dynamic in
Poland, Czech Republic and Italy. Recovery in Italy is ongoing following the disruption
of the flavor ban, although at a slightly slower pace than expected in Q4.
The continued momentum in the region drove Q4 adjusted share growth of +0.9 points
year-on-year to 10.6%, with adjusted IMS volumes reaching 13.5 billion units on a
four-quarter moving average. Q4 shipment volumes increased by +6% against a prior
year comparison which included additional volumes related to the implementation of
the flavor ban, notably in Italy.
The flavor ban is now active in all but 6 EU markets, with a generally consistent pattern
of short-term disruption followed by a return to the pre-ban growth trajectory. Following
an impact of around 2 billion units in 2024, we expect a 2025 impact of around 1 billion
on both shipments and IMS including annualization effects, with the most prominent
effect in the first quarter. We also continue to roll out the ILUMA i device and new
consumable variants such as DELIA and LEVIA to more markets, providing an
increasing choice of taste profiles and price points to adult smokers.

-- 8 of 15 --

9
(SLIDE 16.)
Looking at our key city offtake shares in Europe, we reached a number of important
milestones, with Budapest achieving over 40% share, Rome over 30%, and London
approaching 10%, with Madrid not far behind.
(SLIDE 17.)
Japan delivered outstanding results yet again, with HTU adjusted IMS growth of close
to +13% in both the quarter and the full-year to reach an adjusted Q4 share of 30.6%,
+3.1 points higher year-on-year. This was supported by continuous share growth of
TEREA and SENTIA, as well as the positive traction of the IQOS ILUMA i device as
we reached over 9.5 million adult users.
(SLIDE 18.)
Offtake share in Tokyo for the overall heat-not-burn category reached 52.8% in
December, with the addition of Shizuoka and Hamamatsu to make 10 cities and 5
prefectures exceeding the 50% share threshold. On a national offtake basis, 47% of
the total industry is now smoke-free.
(SLIDE 19.)
Outside of Europe and Japan, adjusted IMS growth continued to grow strongly in Q4.
Promising growth in a number of markets is illustrated by key city shares in Saudi
Arabia, Indonesia and Mexico. Continuous innovation is a key driver of this growth,
with TEREA clove variants and capsules in Indonesia driving an uplift in the quarter,
and some good initial results from the trial of BONDS, our lower-tier offering.
IQOS continues to perform well in Cairo, though offtake share performance was
impacted by the dynamics of the combustible market where competitor supply
normalized, and a very strong prior year quarter following the launch of IQOS ILUMA.
Our Duty Free HTU offtake share increased nicely, as we start to harness the strength
of our multicategory portfolio to drive sales of IQOS, ZYN and VEEV together.
(SLIDE 20.)
Turning now to the U.S., where our IQOS 3 ‘Be The First’ campaign in Austin is
progressing well and we expect to commence direct sales of devices and HTUs in
Austin around the end of Q1. We are seeing high interest from consumers, with over
4,000 adult smokers on our waitlist. As we learn from these initial consumer

-- 9 of 15 --

10
engagements, we are planning the rollout of pilots to other cities. As in Austin, our
focus will be on selective adult consumer engagement and building awareness
through category and brand education in legal-age smoker communities. We do not
assume any significant volumes from U.S. IQOS before the at-scale launch of IQOS
ILUMA, and we continue to hope for an FDA authorization in H2, 2025.
(SLIDE 21.)
Switching categories now to ZYN, where continued strong demand supported Q4 U.S.
shipment volume growth of +42% year-on-year to 165 million cans. Despite ongoing
production limitations, this reflects an acceleration to a near-record sequential
increase of +16 million cans vs. Q3. On a full year basis, shipment volumes grew by
+196 million cans versus 2023, highlighting both the magnitude of growth and the
tremendous efforts made to maximize our production capacity.
ZYN’s category share incrementally improved through the second half, reaching
65.9% in Q4, as our progress in increasing production further supported the growth of
the category.
(SLIDE 22.)
Indeed, category growth slowed significantly during the summer peak of our supply
constraints, as shown on this chart. As the situation started to gradually improve, ZYN
was again leading and outpacing the category.
I am pleased to share that underlying demand for ZYN from adult consumers
continued to grow in Q4, and was higher than previously assumed. We continue to
experience some out-of-stocks at retail, and while production capacity continues to
increase, we now target full normalization sometime in the second half of 2025.
We continue to target around 900 million cans of capacity for the full year from our
Kentucky facility, and as supply continues to improve, we will look to further expand
growth beyond our existing consumer base to other legal-age nicotine users. Our
greenfield site in Colorado is due to come online in early 2026, and we believe we are
well positioned to capture ZYN’s potential over the coming years.
Responsible regulation of the industry is fundamental to supporting sustainable future
growth for this dynamic category. We are therefore encouraged by the recent FDA
authorization for the marketing and sale of all ZYN nicotine pouches currently
marketed in the U.S., following extensive scientific review by the Agency. As
mentioned, this makes ZYN the first and only authorized nicotine pouch in the market.
Among several considerations were the substantially lower amounts of harmful

-- 10 of 15 --

11
constituents versus cigarettes and other smokeless tobacco products, as well as
current low youth usage levels. The FDA’s authorization marks an important step in
the protection of public health by recognizing the role that ZYN can play in providing
better alternatives to cigarettes and other traditional tobacco products for legal-age
adults.
We remain committed to driving industry standards in under-21 prevention, with
policies and initiatives designed to help prevent youth access. Further, combatting
trade in illicit tobacco and nicotine products remains a core priority, and we dedicate a
significant level of resources to support these efforts.
(SLIDE 23.)
ZYN also has an exciting future outside of the U.S. While still in its very early stages,
international nicotine pouch shipments grew by 27 million cans, or +75%, and we
already see strong volume momentum in key international markets such as Pakistan,
South Africa, Mexico, the UK and Global Duty-Free. We launched nicotine pouches in
6 new markets during the quarter to reach a total of 37 worldwide, including Italy,
Romania and Thailand.
(SLIDE 24.)
Within e-vapor, we continue to see strong consumer traction behind VEEV ONE. The
brand holds a top 3 closed pod position in 13 European markets, and held the number
one position in five, including Italy. VEEV plays an important role within our
multicategory strategy, as an increasingly trusted choice for smoke-free category poly-
users and a source of incremental growth with improving economics.
(SLIDE 25.)
Our primary focus for the combustible business is to maximize value over time while
supporting the growth of the smoke-free business. Pricing and cost efficiencies are the
key levers to drive performance, while maintaining our category leadership.
We delivered another robust volume quarter, with growth of +1.1%. All regions
contributed to strong Q4 organic net revenue growth of +6.2%, with gross profit
increasing by +10.8%.
Full-year pricing of +8.7% includes strong contributions from Germany, Egypt and
Turkey. We expect organic 2025 combustible pricing to normalize to +5 to +6%, partly
reflecting Egypt’s move to hyperinflationary accounting in Q4, 2024.

-- 11 of 15 --

12
Category share was flat in Q4, with positive contributions from Turkey and India offset
by declines in Egypt and in Indonesia, with continued growth in the below tier-one
segment. On a full year basis we grew category share +0.1 points, reaching all-time
highs for both Marlboro and our global brands overall.
(SLIDE 26.)
This brings me to the outlook for 2025, where we expect another year of strong growth
from all categories, driving top and bottom-line delivery.
We anticipate a fifth consecutive year of positive volumes, with growth of up to +2%,
notably driven by another year of strong growth in smoke-free products at around +12
to +14%.
For IQOS, we expect a continuation of strong momentum, with the absolute growth in
HTU adjusted IMS volumes expected to be at a similar level to 2024, translating into
+10 to +12% growth. We expect shipment growth to be broadly in line with this double-
digit trajectory, subject to the usual inherent volatility of shipment timing and trade
inventory movements.
We expect ongoing strong growth dynamics within the U.S. nicotine pouch category.
Despite the supply constraints I mentioned before, we forecast a U.S. ZYN volume
shipment range of 780-820 million cans for the year, supported by capacity expansion.
This represents another year of substantial acceleration in volumes, with an expected
increase of approximately 200 to 240 million cans compared to the 196 million can
increase in 2024.
This supports a total PMI forecast of +6% to +8% organic net revenue growth. This
includes a headwind of over 100 basis points due to hyperinflationary accounting in
Egypt and the technical impact of implementing a new commercial model in the
Indonesia below tier-one segment. The change in Indonesia has no effect on OI.
Moving down the P&L, we expect ongoing smoke-free mix effects, operating leverage
and cost efficiencies to drive double-digit adjusted OI growth of +10.5 to +12.5%. This
includes strong gross profit growth, with both gross and adjusted operating margins
forecast to expand in both organic and adjusted dollar terms, at prevailing exchange
rates. We expect SG&A costs to increase broadly in line with net revenues on an
organic basis, as we invest behind our smoke-free products.
We forecast currency-neutral adjusted diluted EPS growth of +10.5% to +12.5%. This
factors in essentially stable net interest expense, and an increase in our effective

-- 12 of 15 --

13
corporate tax rate to approximately 22.5 to 23.5% due to tax increases in line with
OECD pillar two global minimum tax, and the mix of international earnings.
In dollar terms we forecast growth of +7% to +9% to a range of $7.04 to $7.17. This
includes an unfavorable forecast currency impact of 22 cents at prevailing exchange
rates, primarily driven by the broad strength of the dollar, mitigated by our hedging
activities.
For the first quarter of 2025, we expect a strong start to the year with net revenue and
OI growth broadly in line with our full year objectives, despite the leap year
comparison. We forecast HTU adjusted IMS growth of around +10%, which factors in
the larger annualization impact from the EU flavor ban in the quarter, with a
progressive improvement through the year. We forecast shipment volumes of 35 to 36
billion for HTUs and 170 to 180 million cans for U.S. ZYN. We project Q1 adjusted
diluted EPS of $1.58 to $1.63, including a negative currency variance of 4 cents at
prevailing rates, and an effective corporate tax rate 2 to 3 points higher than the prior-
year quarter.
(SLIDE 27.)
With our 2024 delivery and 2025 outlook, we are well positioned to meet or exceed all
metrics of the 2024-26 CAGR targets presented at our 2023 investor day. This is
especially true at the level of OI growth as well as for EPS delivery, where our algorithm
assumed constant 2023 corporate tax rates.
This level of top and bottom-line growth reflects a best-in-class growth profile within
the context of large-cap Consumer Packaged Goods. Importantly, we are also well on
track to deliver high-single-digit adjusted diluted EPS growth in dollar terms across the
2024-2026 period, at prevailing exchange rates.
(SLIDE 28.)
Indeed, we measure our cashflows in dollars and after a record delivery in 2024 we
expect to deliver operating cashflow of around $11 billion for 2025. This is broadly in
line with 2024, once accounting for two non-recurring payments with a total impact of
around $1 billion. While we continue to appeal the German tax surcharge case we
have decided to make a $0.8 billion payment this year, and we also anticipate a final
transition tax payment related to the U.S. Tax Cuts and Jobs Act. We anticipate capital
expenditures of around $1.5 billion, with a large portion of this related to ZYN, as we
prioritize reinvestment behind our smoke-free portfolio.

-- 13 of 15 --

14
Our strong 2024 cash flow and EBITDA growth, combined with a favorable impact
from our Euro balance sheet hedging, allowed us to reduce our net debt to adjusted
EBITDA ratio by 0.5x to 2.66, ahead of our expectations and representing a dramatic
acceleration of our deleveraging. We expect further progress in 2025, placing us on
track for our target ratio of around 2.0x by the end of 2026.
I will now turn it back to Jacek for concluding remarks.
JACEK OLCZAK
(SLIDE 29.)
Thank you, Emmanuel.
In summary, 2024 was a remarkable year for PMI. Our financial results epitomize the
strength of our strategy and the success of our transformation, with underlying
momentum across categories bolstered by our proactive measures on pricing and cost
efficiencies.
I remain confident in our position as the global smoke-free champion, as we continue
to execute on our multicategory strategy with leading premium brands IQOS, ZYN and
VEEV.
Our key strategic priorities for 2025 are clear, as we continue to support the expansion
and development of our smoke-free business both in the U.S. and internationally. We
expect continued strong momentum in 2025, and we remain confident in our ability to
deliver or exceed our 2024-26 growth targets, as we progress towards our ambition of
becoming substantially smoke-free by 2030.
Finally and importantly, our strong growth outlook and highly cash generative business
enables us to continue reinvesting in our smoke-free transformation, while returning
cash to shareholders. In September, we increased our annual dividend for the 17th
consecutive year in line with our long-term commitment.
(SLIDE 30.)
Thank you. Emmanuel and I are now happy to answer your questions.

-- 14 of 15 --

15
JAMES BUSHNELL
(SLIDE 31.)
Before closing our call, I would like to remind you that we will be presenting at the
CAGNY conference on February 19th, and we hope you will be able join either in-
person or virtually. Thank you again for joining us. If you have any follow-up questions,
please contact the Investor Relations team.

-- 15 of 15 --